Seong-Hyun Park

Associate Director

About

I am a team leader of Antibody–Drug Conjugate (ADC) Development at AbTis, a Dong-A ST–affiliated biotech company, where I lead R&D strategy, platform innovation, and external partnerships to advance next-generation ADC therapeutics. My work spans bispecific ADCs, dual-payload systems, site-specific conjugation (AbClick®), linker–payload engineering, in-vitro/in-vivo PoC, and preclinical IND-enabling development. With a multidisciplinary background across protein chemistry, stem-cell–based disease modeling, and oncology, I currently oversee portfolio-scale ADC design, collaborative programs with global CRO/CDMOs, and strategic technology integration for clinical translation. I also drive cross-functional initiatives including manufacturing feasibility, PK/Tox interpretation, organoid-based efficacy modeling, and global licensing preparation. My long-term mission is to build novel ADC that accelerate drug discovery and democratize biologics development - transforming innovative payload chemistry and conjugation science into real therapeutic impact for patients.

Country

United States

City

Nottingham

Industry

Biotechnology

Skill

hESC/hiPSC, Andibody drug conjugation, Mammalian Cell Culture, H. Pylori culture, in vivo assay (tissue isolation, RNA&DNA isolation, primary culture), Enzymatic activity assay, Target Identification, protein modification, RNA Isolation, DNA Isolation, Flow Cytometry, Disease modeling (CMT, DMD, BMD), 3D organoids (skeletal muscle, neuromuscular, lung, intestine), Gene/protein/cell engineering, Protein Purification, Cell Signaling, Chemical screening (protein/cell/organoid based-), Chemical screening (protein/cell based), fluorescent dye conjugation (to antibody), Cancer research

Experience

Associate Director

AbTis (An Antibody Drug Conjugation (ADC) Company)

2024-4 - Present · 2 yrs 6 mos

South Korea

Team Leader of R&D : Product management of ADC projects : ADCs with advanced linker chemistry : Development of ADC pipelines : Antibody Engineering : License Out/In : IND filing

Postdoctoral fellow

The Johns Hopkins University School of Medicine

2019-3 - Present · 7 yrs 7 mos

Baltimore, Maryland, USA

Research area: Disease modeling, drug discovery, regenerative medicine, stem cell, neuroscience. Representative projects 1) Disease modeling with 3D organoids for drug discovery and regenerative medicine (in progress) - Development of human PSC-derived 3D organoids for modeling of Charcot-Marie-Tooth (CMT) disease and Duchenne and Becker Muscular Dystrophy (DMD/BMD)). - Development of Human PSC-derived 3D organoid for the treatment of Volumetric Muscle Loss (VML). 2) Development of hPSC-based drug efficacy test platform (in progress) - Identify the impact of FDA approval drugs on human neural crest-related fetal teratogenesis by using cell-based high-throughput screening. - Promote/enhance myelination of human iPSC-derived Schwann cells by using chemical screening. - Engineering Clinical Trials on a Chip for Dystrophin-Deficient Muscular Dystrophy. Team management and tutoring - hESC & hiPSC culture and differentiation training - FACS analysis training - 1 graduate student, 2 postdoctoral fellows, and collaborators

Postdoctoral Fellow

Yonsei University

2018-9 - 2019-1 · 5 mos

Seoul, Korea

Research area: cancer biology, drug discovery, protein chemistry Ph.D ~ Postdoctoral research in Korea (Sep. 2011- Jan. 2019) Projects -Development of protein/cell-based chemical screening platforms and Anti-cancer drug discovery -Functional and structural studies of proteins -Mechanism studies of apoptosis and autophagy -Development of FRET system using Unnatural Amino Acids -H. pylori infection and detection diagnostic studies Overall workflow -gene Cloning, protein engineering (expression, purification, modification, characterization) -Protein/cell-based compound screening platform development -Bioassay development -Drug discovery & lead optimization -Target identification & Mechanism study -Biosensing 1) Enzymatic activity-based leads screening 2) ELISA-based leads screening 3) FP based lead screening 1) Phenotype screening to find lead inhibitor/inducer of apoptosis/autophagy signaling 2) FACS-based screening to find lead inducer of apoptosis signaling 3) Development of a FRET-based Single cell-level live imaging platform to understand apoptosis signaling 1) Structure-activity relationship (SAR) based optimization 2) Molecular hybridization of drugs to enhance anti-leukemia effect 1) Competition assay, in-gel digestion & MS/MS analysis, RT-PCR analysis, DARTS assay, Thermal shift assay, western blotting, immunocytochemistry, immunoprecipitation, phenotype screening in the presence/absence of known pathway inhibitors for discovered small molecules, NMR study, Molecular docking, SPR, ITC, DLS, etc. 1) pH sensor for diagnosing gastric cell infection caused by H. pylori 2) molecular probe for detecting cellular glycosidase 3) H. pylori detection sensor using fluorescent magnetic nanoparticles Tissue isolation, RNA&DNA isolation, primary culture 8 graduate students, 1 visiting graduate student